Novel Algorithm for Non-Invasive Assessment of Fibrosis in NAFLD

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Sowa, Jan Peter ^a   Heider, Dominik ^a   Bechmann, Lars Peter ^a   Gerken, Guido ^a   Hoffmann, Daniel ^a   Canbay, Ali ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CELL MARKER; CELL PROTEIN; HYALURONIC ACID; PROTEIN M30; PROTEIN M60; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BARIATRIC SURGERY; CELL DEATH; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DECISION TREE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; K NEAREST NEIGHBOR; LEARNING ALGORITHM; LIVER FIBROSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PROGNOSIS; RANDOM FOREST; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; ALGORITHM; ARTIFICIAL INTELLIGENCE; BLOOD; COMPLICATION; FATTY LIVER; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY;

ADULT; ALGORITHMS; ARTIFICIAL INTELLIGENCE; DECISION TREES; FATTY LIVER; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS;

EID: 84876975846     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062439     Document Type: Article

References (36)

1. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G, (2010) A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 53: 372-384.
2. Feldstein AE, (2010) Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin. Liver Dis 30: 391-401.
3. Argo CK, Caldwell SH, (2009) Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 13: 511-531.
4. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
5. Grønbaek K, Christensen PB, Hamilton-Dutoit S, Federspiel BH, Hage E, et al. (2002) Interobserver variation in interpretation of serial liver biopsies from patients with chronic hepatitis C. J. Viral Hepat. 9: 443-449.
6. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, et al. (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128: 1898-1906.
7. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, et al. (2003) Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125: 437-443.
8. Canbay A, Friedman S, Gores GJ, (2004) Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39: 273-278.
9. Feldstein AE, Wieckowska A, Lopez AR, Liu Y-C, Zein NN, et al. (2009) Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50: 1072-1078.
10. Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, et al. (2003) Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 38: 1188-98.
11. Gieseler RK, Marquitan G, Schlattjan M, Sowa J-P, Bechmann LP, et al. (2011) Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C. J. Viral Hepat. 18: 760-767.
12. Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, DeBruyne R, et al. (2010) Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J. Pediatr. Gastroenterol. Nutr. 51: 500-506.
13. Bechmann LP, Gieseler RK, Sowa J-P, Kahraman A, Erhard J, et al. (2010) Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. Liver Int 30: 850-859.
14. Ramadori G, Zöhrens G, Manns M, Rieder H, Dienes HP, et al. (1991) Serum hyaluronate and type III procollagen aminoterminal propeptide concentration in chronic liver disease. Relationship to cirrhosis and disease activity. Eur. J. Clin. Invest. 21: 323-330.
15. McHutchison JG, Blatt LM, De Medina M, Craig JR, Conrad A, et al. (2000) Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J. Gastroenterol. Hepatol. 15: 945-951.
16. Nobili V, Alisi A, Torre G, De Vito R, Pietrobattista A, et al. (2010) Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease. Transl Res 156: 229-234.
17. Malik R, Chang M, Bhaskar K, Nasser I, Curry M, et al. (2009) The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 24: 564-568.
18. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, et al. (2006) Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6: 6.
19. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, et al. (2008) Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47: 455-460.
20. Calès P, Lainé F, Boursier J, Deugnier Y, Moal V, et al. (2009) Comparison of blood tests for liver fibrosis specific or not to NAFLD. J. Hepatol 50: 165-173.
21. Vizzutti F, Arena U, Nobili V, Tarquini R, Trappoliere M, et al. (2009) Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. Ann Hepatol 8: 89-94.
22. Lydatakis H, Hager IP, Kostadelou E, Mpousmpoulas S, Pappas S, et al. (2006) Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int. 26: 864-871.
23. Younossi ZM, Page S, Rafiq N, Birerdinc A, Stepanova M, et al. (2011) A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 21: 431-439.
24. Canbay A, Gieseler RK, Gores GJ, Gerken G, (2005) The relationship between apoptosis and non-alcoholic fatty liver disease: an evolutionary cornerstone turned pathogenic. Z Gastroenterol 43: 211-217.
25. Sajda P, (2006) Machine learning for detection and diagnosis of disease. Annu Rev Biomed Eng 8: 537-565.
26. Kälsch J, Bechmann LP, Kälsch H, Schlattjan M, Erhard J, et al. (2011) Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients. J Nutr Metab 2011: 369168.
27. Frank E, Witten I (1998) Generating Accurate Rule Sets Without Global Optimization. http://www.odysci.com/article/1010112985954253/generating-accurate-rule-sets-without-global-optimization (Accessed December 17, 2012).
28. Breiman L, (2001) Random Forests. Machine Learning 45: 5-32.
29. Cawley GC, Talbot NLC, (2004) Fast exact leave-one-out cross-validation of sparse least-squares support vector machines. Neural Netw 17: 1467-1475.
30. Fawcett T, (2006) An introduction to ROC analysis. Pattern Recognit. Lett. 27: 861-874.
31. Sing T, Sander O, Beerenwinkel N, Lengauer T, (2005) ROCR: visualizing classifier performance in R. Bioinformatics. 21: 3940-3941.
32. Castera L, Pinzani M, (2010) Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut 59: 861-866.
33. Bacchetti P, Boylan R, (2009) Estimating Complex Multi-State Misclassification Rates for Biopsy-Measured Liver Fibrosis in Patients with Hepatitis C. Int J Biostat. 5: 5.
34. Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, et al. (2002) Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 123: 1323-1330.
35. Dechêne A, Sowa J-P, Gieseler RK, Jochum C, Bechmann LP, et al. (2010) Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation. Hepatology 52: 1008-1016.
36. Tomeno W, Yoneda M, Imajo K, Suzuki K, Ogawa Y, et al. (2012) Evaluation of the Liver Fibrosis Index calculated by using real-time tissue elastography for the non-invasive assessment of liver fibrosis in chronic liver diseases. Hepatol. Res.